Study shows improved survival in aggressive acute myeloid leukemia

(University of Texas M. D. Anderson Cancer Center) Patients who relapse in their battle with acute myeloid leukemia may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.